Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack

Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack - Use of DOAC Dipstick in Patients with acute Stroke

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030997

Enrollment

Registered

2023-01-16

Start date

2023-01-01

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I64 I61 G45.9

Interventions

Group 1: Patients = 18 years with acute stroke or transitory ischemic attack (TIA)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: -Symptom-onset within 24 hours before admission (last time point of symptom-free condition within 24 hours) - able to consent with written consent

Exclusion criteria

Exclusion criteria: -Symptom-onset longer than 24 hours before admission (last time point of symptom-free condition not within 24 hours) - unable to consent , or no written consent given

Design outcomes

Primary

Measure	Time frame
- Time of test procedure, including time of initiation and time of result evaluation Rate of DOAC-Dipstick-Test procedures non-feasible within eight hours after admission to stroke unit - Usability of Test results : Rate of color-conversion in one of the Controlpads, clearly interpretable result in automated analysis - Rate of identical results in visual and automated analysis -Rate of positive results of DOAC-Dipstick: Rate of color-conversion of direct-thrombin-inhibitor-Pad or Factor-Xa-inhibitor-pad - Comparability of DOAC-Dipstick and Automated Reader results with DXI-Activity,	—

Measure

Time frame

- Time of test procedure, including time of initiation and time of result evaluation Rate of DOAC-Dipstick-Test procedures non-feasible within eight hours after admission to stroke unit - Usability of Test results : Rate of color-conversion in one of the Controlpads, clearly interpretable result in automated analysis - Rate of identical results in visual and automated analysis -Rate of positive results of DOAC-Dipstick: Rate of color-conversion of direct-thrombin-inhibitor-Pad or Factor-Xa-inhibitor-pad - Comparability of DOAC-Dipstick and Automated Reader results with DXI-Activity,

—

Secondary

Measure	Time frame
-Time of symptom onset of stroke - Type of Stroke (ischemic, hemorrhagic, TIA) - Type and Time of acute therapy of stroke (thrombolysis, thrombectomy, combination of both) - Type of Antidote used in case of intracranial bleeding: Vitamin K, PPSB, Idarucizumab, Andexanet-Alpha, other - NIHSS-Score at hospital admission - GCS -Vital signs at hospital admission - Blood-Laboratry analysis (INR, Quick. aPTT. Haemoglobin, platelett count, creatinine-clearance, thrombin-time if available and factor-Xa-Activity -Intake of medication with anticoagulative ir antiplatelet- properties before stationary admission (DOAC, VKA), heparin or heparinoids, asprin, clopidogrel, other and time of last intake before stationary admission - Rate of positive test results : Rate of color-conversion of direct-thrombin-inhibitor-Pad or factor-XA-pad , if DOAC was taken within previous 48 hours - rate of negative test results, if there was no intake of other medication with anticoagulative or antiplatelett- properties within the previous 48 hours.	—

Measure

Time frame

-Time of symptom onset of stroke - Type of Stroke (ischemic, hemorrhagic, TIA) - Type and Time of acute therapy of stroke (thrombolysis, thrombectomy, combination of both) - Type of Antidote used in case of intracranial bleeding: Vitamin K, PPSB, Idarucizumab, Andexanet-Alpha, other - NIHSS-Score at hospital admission - GCS -Vital signs at hospital admission - Blood-Laboratry analysis (INR, Quick. aPTT. Haemoglobin, platelett count, creatinine-clearance, thrombin-time if available and factor-Xa-Activity -Intake of medication with anticoagulative ir antiplatelet- properties before stationary admission (DOAC, VKA), heparin or heparinoids, asprin, clopidogrel, other and time of last intake before stationary admission - Rate of positive test results : Rate of color-conversion of direct-thrombin-inhibitor-Pad or factor-XA-pad , if DOAC was taken within previous 48 hours - rate of negative test results, if there was no intake of other medication with anticoagulative or antiplatelett- properties within the previous 48 hours.

—

Countries

Germany

Contacts

Public ContactRolf Kern

Klinikum Worms gGmbH

rolf.kern@klinikum-worms.de06241 501-3445

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026